In connection with the implementation by the Ordering Party of the project entitled “Use of matrix metalloproteinase inhibitor to develop an innovative therapy of preventing the development of post-traumatic and post-stroke epilepsy” /POIR.01.01.01-00-0235/20-00/ within Measure 1.1. R&D projects of enterprises, Submeasure 1.1.1 Industrial research and development work implemented by enterprises, co-financed by the European Regional Development Fund, and also in connection with the obligation to apply the principle of competitiveness,
Pikralida sp. z o.o. invites you to submit offers for the organisation and conducting of the early phase clinical trial in healthy volunteers for molecule PKL-021, in compliance with Good Clinical Practice (GCP).
Bids should be submitted electronically to the following e-mail address: pricing_offers@pikralida.eu or via the competitiveness database (link below), in person, by post or by courier to the address of our registered office (date of receipt shall be considered) by the May 14, 2023, until: 11:59 pm.
The request for proposal No. 28/2023 and template documents have been published in the Competitiveness Database: https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl/ogloszenia/154746